LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article: Laparoscopic partial cystectomy for venous malformation of the bladder.

    Radermecker, Lea / Rysselinck, Stéphane / Seront, Emmanuel

    Urology case reports

    2020  Volume 32, Page(s) 101269

    Abstract: Venous malformation (VM) of bladder is uncommon. We report the case of a VM involving bladder that was initially misdiagnosed as endometriosis based on symptomatology, histology and imaging. After failure of hormonal agent and increasing symptoms, a ... ...

    Abstract Venous malformation (VM) of bladder is uncommon. We report the case of a VM involving bladder that was initially misdiagnosed as endometriosis based on symptomatology, histology and imaging. After failure of hormonal agent and increasing symptoms, a laparoscopic partial cystectomy was performed with a rapid improvement. Pathology diagnosis confirmed a VM. The 6-month cystoscopy showed the persistence of a vascularized lesion, reflecting an uncomplete resection. We decided to closely follow the patient and after 24 months, the lesion was stable and our patient remained asymptomatic. This case highlights the importance of considering VM in atypical urological symptoms and bladder lesion.
    Language English
    Publishing date 2020-05-20
    Publishing country United States
    Document type Case Reports
    ZDB-ID 2745459-9
    ISSN 2214-4420
    ISSN 2214-4420
    DOI 10.1016/j.eucr.2020.101269
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Isolated peritoneal carcinomatosis in prostate cancer: from a successful hormonal management to a review of the literature.

    Delchambre, Emilie / Rysselinck, Stéphane / Pairet, Géraldine / Confente, Caterina / Seront, Emmanuel

    Future science OA

    2021  Volume 7, Issue 6, Page(s) FSO707

    Abstract: Metastases from prostate cancer involve mainly the bone compartment. However, visceral metastases are found in up to 49% of metastatic patients, occurring mainly in late stages of the disease, and are correlated with poor outcome. Peritoneal ... ...

    Abstract Metastases from prostate cancer involve mainly the bone compartment. However, visceral metastases are found in up to 49% of metastatic patients, occurring mainly in late stages of the disease, and are correlated with poor outcome. Peritoneal carcinomatosis is rarely described in literature, particularly when not associated with other distant metastatic lesions. We present the management of a patient with prostate cancer progressing on androgen deprivation therapy with description of omental involvement on
    Language English
    Publishing date 2021-04-30
    Publishing country England
    Document type Case Reports
    ISSN 2056-5623
    ISSN 2056-5623
    DOI 10.2144/fsoa-2021-0009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Immune checkpoint inhibitors as a real hope in advanced urothelial carcinoma.

    Seront, Emmanuel / Catala, Gaëtan / Dermine, Alexandre / Lejeune, Sarah / Rysselinck, Stephane

    Future science OA

    2018  Volume 4, Issue 10, Page(s) FSO341

    Abstract: Metastatic urothelial cancer is an aggressive disease associated with a poor prognosis. In the first-line setting, platinum-based chemotherapy is the standard of care but resistance rapidly occurs. After failure of platinum-based therapy and in cisplatin- ...

    Abstract Metastatic urothelial cancer is an aggressive disease associated with a poor prognosis. In the first-line setting, platinum-based chemotherapy is the standard of care but resistance rapidly occurs. After failure of platinum-based therapy and in cisplatin-ineligible patients, therapeutic options are limited. Malignant cells evolve mechanisms to evade immune recognition, including the expression of cell-surface molecules, named immune checkpoints, on tumor and tumor-specific lymphocytes. Immunotherapy, by targeting these checkpoints, represents a new tool to improve the patient outcome in advanced urothelial carcinoma (UC). Recently, the US FDA approved, in a short time, several immune checkpoint inhibitors in metastatic UC, both after failure of platinum-based therapy and in first-line setting in cisplatin-ineligible patients. This article aims to review the place of immunotherapy in advanced UC.
    Language English
    Publishing date 2018-10-04
    Publishing country England
    Document type Journal Article ; Review
    ISSN 2056-5623
    ISSN 2056-5623
    DOI 10.4155/fsoa-2018-0033
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top